Bruno Strigini

Bruno Strigini is an accomplished investor and advisor currently serving as the Chairman of the board at Owkin, a leading AI and machine learning company focused on healthcare. They are also a Partner at OneHealth Partners and have founded ARVIC AG, a healthcare consulting and investment firm in Basel, Switzerland. Previously, Bruno held the position of CEO at Novartis Oncology, managing a global team of over 10,000 associates to innovate cancer care. Their extensive experience includes significant roles at Merck & Co., Schering-Plough, UCB, and SmithKline Beecham, where they contributed to various aspects of international operations and marketing. Bruno holds a PharmD from the University of Montpellier, an MBA from IMD Lausanne, and a Master’s degree in microbiology from Heriot-Watt University, with additional recognition as a member of the French Academy of Pharmacy and an honorary doctorate from UIMP in Spain.